These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062 [TBL] [Abstract][Full Text] [Related]
4. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593 [TBL] [Abstract][Full Text] [Related]
6. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623 [TBL] [Abstract][Full Text] [Related]
7. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Nadal E; Giné E; Bladé J; Esteve J; Rosiñol L; Fernández-Avilés F; Marin P; Martinez C; Rovira M; Urbano-Ispizua A; Carreras E; Montserrat E Bone Marrow Transplant; 2004 Jan; 33(1):61-4. PubMed ID: 14704657 [TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma. Bommier C; Talbot A; Harel S; Cuccuini W; Gérard L; Arnulf B Hematol Oncol; 2020 Oct; 38(4):517-522. PubMed ID: 32569436 [TBL] [Abstract][Full Text] [Related]
9. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672 [TBL] [Abstract][Full Text] [Related]
10. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Kebriaei P; Madden T; Kazerooni R; Wang X; Thall PF; Ledesma C; Nieto Y; Shpall EJ; Hosing C; Qazilbash M; Popat U; Khouri I; Champlin RE; Jones RB; Andersson BS Biol Blood Marrow Transplant; 2011 Mar; 17(3):412-20. PubMed ID: 20674757 [TBL] [Abstract][Full Text] [Related]
11. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168 [TBL] [Abstract][Full Text] [Related]
12. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815 [TBL] [Abstract][Full Text] [Related]
13. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354 [TBL] [Abstract][Full Text] [Related]